Value Microcaps Zip Code Changers

[Bobwins]

ATE.v +.035 to C$.315

Antibe moving up in anticipation of phase II results. Company has confirmed that safety portion of phase II has been completed and CRO is collecting results. Top line results will be released next week.

Study involved testing whether ATB-346 was safer on gastrointestinal tract than standard naproxen(aleve). Each healthy patient had an endoscopy of trachea before and after taking ATB-346. Other healthy patients will take a standard dosage of naproxen.

This is the main difference between ATB-346 and naproxen so results of this phase will be crucial to whether ATB-346 advances. If successful, these results should allow ATE to get a big partner for phase III trials and eventual commercialization.

With all the publicity about addictive opiods for pain, ATB-346 could easily be a billion dollar drug, allowing pain relief for arthritis suffers without GI tract damage or danger of addiction. Arthritis patients are going to be on whatever pain reliever they choose for an extended time period so bad side effects are very important.